Predict your next investment

Venture Capital
axilcapital.com

See what CB Insights has to offer

Investments

13

Portfolio Exits

3

Funds

1

About Axil Capital

Axil Capital is a venture capital firm based in Tokyo, Japan, specializing in biomedical & healthcare technology investments, with emphasis on supporting the growth of early-stage ventures.

Axil Capital Headquarter Location

Nihonbashi Life Science Building 2, Room 504 3-11-5 Nihonbashi-Honcho, Chuo-ku

Tokyo, 103-0023,

Japan

+81-3-3527-2212

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Axil Capital News

Suono Bio, Inc. Announces Oversubscribed Series A Funding Round Led by Axil Capital and Mizuho Securities Principal Investment

Jul 13, 2021

July 13, 2021 08:00 AM Eastern Daylight Time FOXBOROUGH, Mass.--( BUSINESS WIRE )--Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has raised an $8.5 million Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors. Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its pipeline. Suono Bio’s platform technology enables the rapid, targeted delivery of drugs, including gene therapies, for the first time, enabling the use of the right drug in the right patient. Suono Bio leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious diseases. The company was founded by Professor Langer, Professor Giovanni Traverso, from the Department of Mechanical Engineering at MIT and a gastroenterologist and biomedical engineer at Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. Publications on the technology have appeared in Nature, Gastroenterology, and Science Translational Medicine, and the company has previously announced strategic investments from FUJIFILM Corporation and NGK Spark Plug Co., LTD. “Suono Bio’s technology is poised to accelerate novel therapeutics to the clinic by finally overcoming the challenges with delivering drugs like DNA or RNA,” said Frederick Shane, Managing Partner of Axil, who joined the Board of Directors. “Their technology spans beyond a single product or asset to a whole new platform of products to treat debilitating diseases and we are thrilled to lead this round,” he added. “We are thrilled to have marquee investors involved with Suono Bio and speaks to the rapid pace with which the team has taken a conceptual technology from Prof. Langer’s lab and operationalized it to address pressing health issues,” said Scott Kellogg, CEO. Proceeds from the Series A financing will allow completion of the development of the company’s first product for treating ulcerative colitis, readying it for human trials, and further the development of the overall technology platform. “The ability to deliver macromolecules, including DNA and RNA based medicines outside of the liver and in a formulation-independent approach could be applied to many diseases and benefit a tremendous number of patients,” said Professor Robert Langer, co-founder and Board Member. “We are excited to be able to advance the development of an approach which has the capacity to rapidly and effectively deliver a broad array of therapeutics from small molecules to nucleic acids,” added Professor Giovanni Traverso, co-founder and Board Member. ABOUT SUONO BIO Suono Bio is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform was developed at The Massachusetts Institute of Technology in Professor Robert Langer’s laboratory and enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. For more information, please visit www.suonobio.com . ABOUT AXIL CAPITAL Axil Capital Partners is a Tokyo based venture capital firm specializing in biomedical & healthcare technology investments with an emphasis on supporting the growth of early-stage ventures. The firm invests in a wide range of companies in the life sciences space, with a particular focus on cross-disciplinary technologies that can transform the future of healthcare. For more information, please visit https://www.axilcapital.com/ . Contacts

Axil Capital Investments

13 Investments

Axil Capital has made 13 investments. Their latest investment was in Aibios as part of their Series A on June 6, 2021.

CBI Logo

Axil Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/11/2021

Series A

Aibios

$7.02M

No

2

3/25/2021

Series A

Suono Bio

$8.5M

Yes

3

3/3/2021

Series B

TechsoMed

$7M

No

5

11/10/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/1/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/11/2021

3/25/2021

3/3/2021

11/10/2020

9/1/2020

Round

Series A

Series A

Series B

Series B

Series A

Company

Aibios

Suono Bio

TechsoMed

Subscribe to see more

Subscribe to see more

Amount

$7.02M

$8.5M

$7M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

5

10

10

Axil Capital Portfolio Exits

3 Portfolio Exits

Axil Capital has 3 portfolio exits. Their latest portfolio exit was Perseus Proteomics on June 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2021

IPO

$99M

Public

3

10/2/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/3/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/22/2021

10/2/2020

10/3/2019

Exit

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

3

10

10

Axil Capital Fund History

1 Fund History

Axil Capital has 1 fund, including Axil Life Science & Healthcare Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Axil Life Science & Healthcare Fund I

1

Closing Date

Fund

Axil Life Science & Healthcare Fund I

Fund Type

Status

Amount

Sources

1

Axil Capital Team

2 Team Members

Axil Capital has 2 team members, including current Managing Partner, Fred Shane.

Name

Work History

Title

Status

Fred Shane

Managing Partner

Current

Frederick Shane

Managing Partner

Current

Name

Fred Shane

Frederick Shane

Work History

Title

Managing Partner

Managing Partner

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.